Pacts In Medtech: BI, Inflammasome Work On Retinal Disease; Takeda And Prometheus Take On IBD
Derived from Strategic Transactions, Informa's premium source for tracking life-sciences deals, the bimonthly Pacts In Medtech feature highlights notable technology alliances, research and development partnerships and commercial collaborations. This edition covers industry pacts that were signed in September and October 2019.
Boehringer Ingelheim International GmbH and Inflammasome Therapeutics Inc. agreed to co-develop up to three candidates for retinal diseases.
BI will provide up to $160m in up-front, R&D, and milestone payments, plus tiered royalties and additional commercialization milestones. The...